Trump Tariffs: Market Psychology, Earnings Season, and Global Equity Insights

Impact of Tariffs on Market Psychology

• 💡 US tariffs have dominated market conversations, with statements from the Trump administration often being contradictory.
• ⚠️ Tariffs are viewed as a developing story, not yet in the rearview mirror, with potential to inject inflation into the economy.
• 🧐 Companies have made adjustments, such as building inventories, to mitigate the full impact of tariffs without directly affecting earnings.

Earnings Season and Federal Reserve Outlook

• 📊 This earnings season is critical for understanding the real effects of tariffs and how corporations have adapted.
• 📉 The market is pricing in two rate cuts before year-end, but the Fed is taking a wait-and-see approach to assess the actual economic impact.
• ⏳ It will take time to see the true effects of tariffs that cannot be circumvented by corporate adjustments.

Company Exposure and Market Resilience

• 🌍 All companies are exposed to tariffs to varying degrees, depending on their industry and strategy.
• ✈️ Delta Airlines is seen as a microcosm of adaptation, reimplementing earnings guidance with better clarity on tariff impacts.
• 📈 This clarity is crucial for investor confidence in earnings estimates and the valuation of the S&P 500.

Global Equity Perspectives

• 📉 Growth outlook is uncertain and likely on a downward trajectory due to tariffs, viewed by the market as a negotiating tool.
• 🌏 Asia faces varied impacts, with countries like Vietnam initially at risk but negotiating positive outcomes, while the auto sector in Japan is penalized.
• 🇨🇳 China presents opportunities in tech and the consumer/financial services sector, with potential catalysts in supply-side reforms to address oversupply and competition.
• 🇪🇺 European markets show promise, with Germany's infrastructure plan expected to boost GDP and construction sector benefiting from stimulus and loose monetary policy.

Technology and Supply Chain Considerations

• 🤖 China Tech is showing agility in adapting to US export controls and restrictions, with US tech CEOs acknowledging China's ability to manage constraints.
• 💊 The pharmaceutical industry requires a case-by-case analysis of supply chains and manufacturing footprints to understand tariff impacts, with a trend towards onshoring manufacturing back to the US.
• 📈 Companies with manufacturing and supply chains in the US are largely insulated from tariff impacts on exports to the US.